Corporate Breaking News
Corporate Breaking News
Home : OxThera Receives Positive Decision From EMA on Paediatric Investigational Plan (PIP) for Treatment of Primary Hyperoxaluria With Oxalobacter formigenes
Aug 23
2019

OxThera Receives Positive Decision From EMA on Paediatric Investigational Plan (PIP) for Treatment of Primary Hyperoxaluria With Oxalobacter formigenes

STOCKHOLM, Sweden, Aug. 23, 2019 /PRNewswire/ -- OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), today announced that, based on a positive opinion from the Paediatric Committee (PDCO), the EMA has agreed to...
Source:https://www.prnewswire.com:443/news-releases/oxthera-receives-positive-decision-from-ema-on-paediatric-investigational-plan-pip-for-treatment-of-primary-hyperoxaluria-with-oxalobacter-formigenes-300905995.html
 
Related News
» Nearly 20,000 Dancers Gather at Kochi "Yosakoi Festival," Many from U.S., Europe and Asia
» FLNG Market Annual Production to Hit 300 Metric Ton by 2024: Global Market Insights, Inc.
Home
About us
Archive
Sitemap
Powered By Corporate Breaking News.com Home| About us| Archive News| Sitemap